Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
暂无分享,去创建一个
R Hartmann | G. Henze | B. Kornhuber | G. Janka-Schaub | D. Niethammer | G Janka-Schaub | R. Fengler | R. Hartmann | H. Riehm | G Henze | R Fengler | B Kornhuber | D Niethammer | H Riehm | R. Fengler | G. Henze
[1] G. Henze,et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990 .
[2] J. Hermans,et al. The significance of an isolated central nervous system relapse, occurring as first relapse in children with acute lymphoblastic leukemia , 1989, Cancer.
[3] W. Hiddemann,et al. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. , 1988, Blood.
[4] C. Pui,et al. Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. , 1988, Medical and pediatric oncology.
[5] S. George,et al. Second central nervous system prophylaxis in children with acute lymphoblastic leukemia who relapse after elective cessation of therapy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Thomas,et al. Marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 1987, Blood.
[7] R. Bender,et al. Membrane transport of methotrexate in human lymphoblastoid cells. , 1978, Cancer research.
[8] J. Belasco,et al. Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children , 1990, Cancer.
[9] J. Schornagel,et al. Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake. , 1989, Leukemia research.
[10] R. Gale,et al. WHICH TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA IN SECOND REMISSION? , 1987, The Lancet.
[11] G. Henze,et al. Risk of CNS relapse after systemic relapse of childhood acute lymphoblastic leukemia. , 1990, Haematology and blood transfusion.
[12] G. Rivera,et al. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. , 1988, Blood.
[13] S. Srimatkandada,et al. Methotrexate resistant cells as targets for selective chemotherapy. , 1985, Advances in enzyme regulation.
[14] G. Henze,et al. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A Report From the BFM Study Group. , 1981, Haematology and blood transfusion.
[15] F. Lampert,et al. Acute Lymphoblastic Leukaemia , 1986 .
[16] P. Steinherz,et al. Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood , 1989, Cancer.
[17] R. Levinsky,et al. BONE-MARROW TRANSPLANTATION HAS A LIMITED ROLE IN PROLONGING SECOND MARROW REMISSION IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIA , 1986, The Lancet.
[18] F. Behm,et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.
[19] S L George,et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.
[20] R. Gelber,et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.
[21] D. Rogers,et al. Outcome following late marrow relapse in childhood acute lymphoblastic leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.